To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

November 15, 2019___

Today's Rundown

Featured Story

After BMS said no, Roche puts $1.4B on the table for Promedior, boosting fibrotic pipeline

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.

Top Stories

Sarepta pays StrideBio $48M for preclinical gene therapies

Sarepta is set to pay $48 million upfront to work with StrideBio on gene therapies. The deal gives Sarepta exclusive licenses to four CNS targets plus an option to pay a further $42.5 million to add another four targets to the deal.

Arrowhead R&D lead steps down, biotech vets step in

Californian RNA biotech Arrowhead will lose its chief operating officer and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

EpicentRx raises $35M to fund late-phase lung cancer trial

EpicentRx has raised $35 million for late-phase development of RRx-001. The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Could this immuno-oncology combo treat metastatic prostate cancer?

Researchers at MD Anderson Cancer Center discovered that when prostate tumors spread to bone and destroy it, massive amounts of a protein called TFG-beta are produced, which prevents immune-boosting drugs from attacking the cancer. Combining a checkpoint inhibitor with an anti-TGF-beta drug could be the answer, they believe.

EuroBiotech Report—AstraZeneca's lupus filing, Roche SMA data, Kiadis cuts, Genfit and Merck

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

FiercePharmaAsia—Sandoz bets, Lupin sells in Japan; Dr. Reddy’s Zantac loss; Aslan’s varlitinib flop

Novartis' Sandoz doubled down on Japan with a €400 million Aspen deal, as Lupin retreated from the country. Dr. Reddy's detailed its loss from the U.S. recall of generic Zantac. Aslan's lead drug, pan-HER inhibitor varlitinib, failed yet another critical trial. And more.

Chutes & Ladders—Abbott CEO White out after 21 years on the job

Abbott CEO Miles White is set to step down after 21 years; Lonza head Marc Funk is out after just a year; and Progenics' Mark Baker could be out after a board shuffle.

Enrollment Showcase

A Credential for the Future of Health Care

Join the future of health care with the flexibility and convenience of an online program.

Resources

[Whitepaper] Medical Affairs 2025 Excellence in the Era of Precision Medicine

Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade.

[Whitepaper] The State of Real-World Evidence in Biopharma

This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow.

[Whitepaper] IBM Clinical Development: Key solutions for more efficient clinical research

IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology.

[Whitepaper] How Big is the US Market for Medical Devices and Technologies?

Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting.

[Whitepaper] The importance of early key opinion leader outreach in the biologics and biosimilars marketplace

Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more.

[Whitepaper] 5 Best Practices for Marketing Medical Devices

Discover solutions to the most common challenges faced by medical device companies.

[Whitepaper] The Impact of Step-Therapy Policies on Patients

Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system.

[Whitepaper] Q2 2019 Biopharma licensing report

18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights.

[Whitepaper] Synthesizing Success: Six Principles For Getting Pharmaceutical Development Right From The Start

Is your API development on track?

[Infographic] Implement the Patient Voice to Build an Effective Engagement App

Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app.

[eBook] Customer Experience: Shaping Digital Healthcare

Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve

[Whitepaper] How to succeed by failing faster

This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy.

[Article] 8 Compelling Reasons Why Businesses Need To Be In The Cloud Now!

Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business.

[Whitepaper] Innovative Funding Models for Treatment of Cancer and Other High-Cost Chronic Noncommunicable Diseases

A global landscape study of funding trends and innovations.

[Case Study] Clinical Supply Management

Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study.

[Video] Demand Led Services and Clinical Supply Efficiency

Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels.

[eBook] Strategies for Efficient Clinical Supply Management and Forecasting

Download the eBook to explore a proactive approach for clinical supply management.

Events